Meetings; Sunshine Act, 6921 [E9-2970]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 27 / Wednesday, February 11, 2009 / Notices
1301.34(a), this is notice that on January
6, 2009, Roche Diagnostics Operations
Inc., Attn: Regulatory Compliance, 9115
Hague Road, Indianapolis, Indiana
46250, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Schedule
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
Alphamethadol (9605) ..................
Cocaine (9041) .............................
Ecgonine (9180) ...........................
Methadone (9250) ........................
Morphine (9300) ...........................
I
I
I
II
II
II
II
mstockstill on PROD1PC66 with NOTICES
The company plans to import the
listed controlled substances for the
manufacture of diagnostic products for
distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 13, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: February 5, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–2904 Filed 2–10–09; 8:45 am]
DEPARTMENT OF JUSTICE
17:58 Feb 10, 2009
Jkt 217001
FEDERAL MINE SAFETY AND HEALTH
REVIEW COMMISSION
Drug Enforcement Administration
Meetings; Sunshine Act
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 6, 2009,
Siegfried (USA), Inc., 33 Industrial Park
Road, Pennsville, New Jersey 08070,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Oxymorphone (9652) ...................
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 13, 2009.
Dated: February 5, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–2910 Filed 2–10–09; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Nov<24>2008
6921
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
February 2, 2009.
TIME AND DATE: 10 a.m., Thursday,
February 12, 2009.
PLACE: The Richard V. Backley Hearing
Room, 9th Floor, 601 New Jersey
Avenue, NW., Washington, DC.
STATUS: Open.
MATTERS TO BE CONSIDERED: The
Commission will consider and act upon
the following in open session: Secretary
of Labor v. SCP Investments, LLC,
Docket Nos. SE 2006–148–M and SE
2006–163–M. (Issues include whether
the Administrative Law Judge properly
concluded that certain citations and
orders issued to the operator should be
vacated because the MSHA inspector
did not allow the operator to exercise
any walkaround rights during the
inspection in question.)
Any person attending this meeting
who requires special accessibility
features and/or auxiliary aids, such as
sign language interpreters, must inform
the Commission in advance of those
needs. Subject to 29 CFR 2706.150(a)(3)
and 2706.160(d).
FOR FURTHER INFORMATION CONTACT: Jean
Ellen (202) 434–9950 / (202) 708–9300
for TDD Relay / 1–800–877–8339 for toll
free.
Jean H. Ellen,
Chief Docket Clerk.
[FR Doc. E9–2970 Filed 2–9–09; 11:15 am]
BILLING CODE 6735–01–P
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
Institute of Museum and Library
Services; Sunshine Act Meeting of the
National Museum and Library Services
Board
AGENCY: Institute of Museum and
Library Services (IMLS), NFAH.
ACTION: Notice of meeting.
SUMMARY: This notice sets forth the
agenda of the forthcoming meeting of
the National Museum and Library
Services Board. This notice also
describes the function of the Board.
Notice of the meeting is required under
the Sunshine in Government Act.
Time and Date: Wednesday, February
18, 2009 from 1:30 p.m. to 4:30 p.m.
Agenda: Sixteenth National Museum
and Library Services Board Meeting:
I. Welcome.
II. Approval of Minutes.
E:\FR\FM\11FEN1.SGM
11FEN1
]]>Agencies
[Federal Register Volume 74, Number 27 (Wednesday, February 11, 2009)]
[Notices]
[Page 6921]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-2970]
=======================================================================
-----------------------------------------------------------------------
FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION
Meetings; Sunshine Act
February 2, 2009.
TIME AND DATE: 10 a.m., Thursday, February 12, 2009.
PLACE: The Richard V. Backley Hearing Room, 9th Floor, 601 New Jersey
Avenue, NW., Washington, DC.
STATUS: Open.
MATTERS TO BE CONSIDERED: The Commission will consider and act upon the
following in open session: Secretary of Labor v. SCP Investments, LLC,
Docket Nos. SE 2006-148-M and SE 2006-163-M. (Issues include whether
the Administrative Law Judge properly concluded that certain citations
and orders issued to the operator should be vacated because the MSHA
inspector did not allow the operator to exercise any walkaround rights
during the inspection in question.)
Any person attending this meeting who requires special
accessibility features and/or auxiliary aids, such as sign language
interpreters, must inform the Commission in advance of those needs.
Subject to 29 CFR 2706.150(a)(3) and 2706.160(d).
FOR FURTHER INFORMATION CONTACT: Jean Ellen (202) 434-9950 / (202) 708-
9300 for TDD Relay / 1-800-877-8339 for toll free.
Jean H. Ellen,
Chief Docket Clerk.
[FR Doc. E9-2970 Filed 2-9-09; 11:15 am]
BILLING CODE 6735-01-P
